Literature DB >> 19049823

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.

M Pedersen1, L Rönnstrand, J Sun.   

Abstract

Activating mutations of codon 816 of the Kit gene have been implicated in malignant cell growth of acute myeloid leukemia (AML), systemic mastocytosis and germ cell tumors. Substitution of aspartic acid with valine (D816V) renders the receptor independent of ligand for activation and signaling. Wild-type c-Kit is a tyrosine kinase receptor that requires its ligand, stem cell factor (SCF), for activation. Several isoforms of c-Kit exist as a result of alternative mRNA splicing, of which two are characterized by the presence or absence of four amino acids (GNNK- and GNNK+, respectively) in the extracellular domain. The two isoforms show differences in signal transduction and biological activities and the shorter isoform seems to be highly expressed than the longer isoform in human malignancies. In this study we analysed the signal transduction downstream of the oncogenic c-Kit mutant D816V in an isoform specific context, using the hematopoietic cell line Ba/F3 stably transfected with the different versions of isoform and mutant receptor. Our data show that in contrast to the differences shown in the activation of wild-type c-Kit isoforms, both isoforms of c-Kit/D816V are constitutively phosphorylated to the same extent. By the use of Western blot analysis we investigated the activation of different signaling proteins and found that both D816V/GNNK- and D816V/GNNK+ constitutively phosphorylated Gab2, Shc, SHP-2 and Cbl to almost the same extent as c-Kit/GNNK-. In addition, both isoforms of c-Kit/D816V induced SCF-independent cell survival and proliferation equally well. This is in contrast to wild-type c-Kit, where c-Kit/GNNK- induced better cell survival and stronger proliferation than c-Kit/GNNK+, and both required stimulation with SCF. Taken together, these findings reveal that the differences in downstream signal transduction and biological responses between the two GNNK isoforms are eliminated by the D816V mutant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049823     DOI: 10.1016/j.cellsig.2008.11.008

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  13 in total

1.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

Review 2.  Mast cell homeostasis and the JAK-STAT pathway.

Authors:  J K Morales; Y T Falanga; A Depcrynski; J Fernando; J J Ryan
Journal:  Genes Immun       Date:  2010-06-10       Impact factor: 2.676

Review 3.  Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

Authors:  Sophie Park; Nicolas Chapuis; Jérôme Tamburini; Valérie Bardet; Pascale Cornillet-Lefebvre; Lise Willems; Alexa Green; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

4.  KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.

Authors:  Eunice Ching Chan; Yun Bai; Geethani Bandara; Olga Simakova; Erica Brittain; Linda Scott; Kimberly D Dyer; Amy D Klion; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  Exp Hematol       Date:  2013-06-04       Impact factor: 3.084

5.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Authors:  Eunice Ching Chan; Yun Bai; Arnold S Kirshenbaum; Elizabeth R Fischer; Olga Simakova; Geethani Bandara; Linda M Scott; Laura B Wisch; Daly Cantave; Melody C Carter; John C Lewis; Pierre Noel; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

6.  Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.

Authors:  Penelope Pelczar; Arne Zibat; Willemijn A van Dop; Jarom Heijmans; Annalen Bleckmann; Wolfgang Gruber; Frauke Nitzki; Anja Uhmann; Maria V Guijarro; Eva Hernando; Kai Dittmann; Jürgen Wienands; Ralf Dressel; Leszek Wojnowski; Claudia Binder; Takahiro Taguchi; Tim Beissbarth; Pancras C W Hogendoorn; Cristina R Antonescu; Brian P Rubin; Walter Schulz-Schaeffer; Fritz Aberger; Gijs R van den Brink; Heidi Hahn
Journal:  Gastroenterology       Date:  2012-10-03       Impact factor: 22.682

7.  An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

Authors:  Rafal Dziadziuszko; Anh T Le; Anna Wrona; Jacek Jassem; D Ross Camidge; Marileila Varella-Garcia; Dara L Aisner; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2016-04-09       Impact factor: 15.609

8.  Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles.

Authors:  Seema Singh; Rakesh Verma; Anamika Pradeep; Karen Leu; R Bruce Mortensen; Peter R Young; Miho Oyasu; Peter J Schatz; Jennifer M Green; Don M Wojchowski
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

9.  TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.

Authors:  Sebastian Drube; Franziska Weber; Christiane Göpfert; Romy Loschinski; Mandy Rothe; Franziska Boelke; Michaela A Diamanti; Tobias Löhn; Julia Ruth; Dagmar Schütz; Norman Häfner; Florian R Greten; Ralf Stumm; Karin Hartmann; Oliver H Krämer; Anne Dudeck; Thomas Kamradt
Journal:  Oncotarget       Date:  2015-10-06

10.  Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance.

Authors:  Xiao-Wei Hou; Chen-Guang Bai; Xiao-Hong Liu; Cen Qiu; Ling Huang; Jing-Jing Xu; DA-Lie Ma
Journal:  Oncol Lett       Date:  2012-11-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.